Abeona Therapeutics' (ABEO) "Buy" Rating Reiterated at HC Wainwright

Abeona Therapeutics (NASDAQ:ABEO - Get Free Report)'s stock had its "buy" rating reissued by equities researchers at HC Wainwright in a research note issued on Thursday, Benzinga reports. They presently have a $15.00 target price on the biopharmaceutical company's stock. HC Wainwright's price target would indicate a potential upside of 137.34% from the company's previous close.

A number of other research firms have also recently commented on ABEO. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $18.00 target price on shares of Abeona Therapeutics in a research note on Tuesday. StockNews.com upgraded Abeona Therapeutics from a "sell" rating to a "hold" rating in a research note on Tuesday, September 10th.

Abeona Therapeutics Stock Performance

Shares of ABEO stock traded down $0.04 during trading hours on Thursday, reaching $6.32. 142,439 shares of the company traded hands, compared to its average volume of 436,422. The company has a debt-to-equity ratio of 0.22, a current ratio of 7.48 and a quick ratio of 7.48. The company has a market cap of $258.89 million, a P/E ratio of -1.96 and a beta of 1.53. The firm has a 50-day moving average price of $6.02 and a 200 day moving average price of $5.18. Abeona Therapeutics has a 12-month low of $3.05 and a 12-month high of $9.01.

Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) last released its earnings results on Monday, August 12th. The biopharmaceutical company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.42). As a group, sell-side analysts predict that Abeona Therapeutics will post -1.28 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Abeona Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of ABEO. Acadian Asset Management LLC purchased a new position in Abeona Therapeutics in the first quarter worth $91,000. Western Standard LLC raised its stake in Abeona Therapeutics by 68.5% in the first quarter. Western Standard LLC now owns 1,361,489 shares of the biopharmaceutical company's stock valued at $9,871,000 after buying an additional 553,377 shares during the last quarter. Rosalind Advisors Inc. acquired a new stake in Abeona Therapeutics in the second quarter worth about $7,420,000. Bank of New York Mellon Corp increased its holdings in shares of Abeona Therapeutics by 2.0% during the second quarter. Bank of New York Mellon Corp now owns 121,453 shares of the biopharmaceutical company's stock valued at $515,000 after acquiring an additional 2,434 shares in the last quarter. Finally, Renaissance Technologies LLC grew its holdings in shares of Abeona Therapeutics by 581.6% during the second quarter. Renaissance Technologies LLC now owns 503,293 shares of the biopharmaceutical company's stock valued at $2,134,000 after buying an additional 429,456 shares during the last quarter. Hedge funds and other institutional investors own 80.56% of the company's stock.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.